Test Code Ca 19-9 Ca 19-9
Aliases
Carbohydrate Antigen 19-9
Useful For
Aids in the diagnosis of Pancreatic Cancer
Patient Preparation
No special patient preparation required
Collection Method
Venous collection
Minimum Volume
- Adults: 1 mL
- Pediatric: 0.8 ml
Container
Lt Green / Plasma Separator / Lithium Heparin
Preferred Specimen
Light Green Top (lithium heparin) plasma
Acceptable Specimens
Serum:
- Gold Top SST
- Red Top
Plasma:
- Light Geen Top (lithium heparin)
- Purple or Pink Top (K2/K3 EDTA)
Reference or Target Ranges
2 – 35 U/mL
Reportable Units
U/mL
Critical Value
Not defined for this assay
Reasons for Rejection
Hemolysis Threshold | 1000 mg/dL |
Icterus Threshold | 66 mg/dL |
Lipemia Threshold | 1500 mL |
Other | QNS, contaminated, improperly Labeled, improper specimen type |
Specimen Stability
Ambient | 5 days |
Refrigerated (4°C to 8°C) | 14 days |
Frozen(-40°C to 0°C) | 3 months |
Performance Information
Days and Time Performed | 24/7 |
Expected Turn Around Time | Routine: 4 hours from arrival in lab |
Stat Availability | No |
Performing Bench | UH Chemistry, WCH Chemistry |
Methodology/Method Description | Roche Cobas – Two site immunoenzymatic sandwich assay |
Ca 19-9 values determined on patient samples by different testing procedures cannot be directly compared with one another and could be the cause of erroneous medical interpretations.
Additional Information/Important Notes
Important Note:
Patients known to be genotypically negative for Lewis blood group antigens will be unable to produce the CA 19-9 antigen even in the presence of malignant tissue. Phenotyping for the presence of Lewis blood group antigen may be insufficient to detect true Lewis antigen negative individuals. Even patients who are genotype positive for the Lewis antigen may produce varying levels of CA 19-9 as the result of gene dosage effect.
CPT Codes
86301